Notable Labs, a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer, completed the merger with VBL Therapeutics, a biopharmaceutical company. Financial terms were not disclosed. “This is an important milestone for Notable as we continue to advance the demonstrated value of the PPMP. The merger will add additional capital to accelerate our continued development of Volasertib for the treatment of AML in PPMP-predicted responding patients. As a publicly traded company, we will continue to evaluate potential additional programs and assets where PPMP is especially suited for risk-reducing and fast-tracking therapeutic development,” Thomas Bock, Notable Labs CEO.